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In 2003, China took measures to contain an outbreak of ‘flu-
like illness’ [1]; when the same disease (which came to be
called severe acute respiratory syndrome, SARS) began to
appear in other countries, the World Health Organization
initiated a global response [2]. This incident highlighted, on
a world stage, the need for rapid and accurate techniques for
pathogen identification. Failure to have such tools puts lives
at risk by severely hampering containment and effective vac-
cination strategies. 
Over the past few decades, the identification and characteri-
zation of infectious agents has been refined and improved,
resulting in highly sensitive and precise methodologies that
will soon be able to measure individual molecules. This sen-
sitivity comes at a cost, however, in terms of time, complex-
ity of assay, and robustness of measurements, and this can
have a negative impact on patient care. The prognosis for the
majority of serious infections is vastly improved by early
intervention, so the development of rapid detection and
identification methods is essential, but this must not come at
the expense of sensitivity. In the case of hepatitis C infection,
for example, diagnosis needs low levels of virus to be
detected [3], and this demands a high level of assay sensitiv-
ity. For these reasons there is an ever-increasing require-
ment for rapid, sensitive technologies that provide better
diagnosis and clinical management of infectious diseases. In
an effort to address that need, modern medicine has seen a
revolution in new high-throughput approaches. Advances in
genomics, microarrays and imaging technologies, in particu-
lar, have revolutionized the way in which infectious-disease
problems are being addressed. Here, we briefly examine how
such technologies are being applied to the detection and
identification of viruses and the impact such systems might
have in the clinic.
DNA and protein microarray approaches
Until recently, virus detection and identification in the clin-
ical setting has been centered around immunological or
PCR-based techniques. One of the primary immunological
techniques is the use of enzyme-linked immunosorbent
assays (ELISAs) for the detection of circulating virus-spe-
cific antibodies. By contrast, reverse transcriptase (RT)-
PCR is used to detect the presence of viral genomes or
specific viral genes. A combined approach using both tech-
niques overcomes detection problems when either the
infection produces a weak antibody response or when virus-
specific transcripts are in low abundance. Both these
approaches have well documented limitations, however.
Immunological tests are hampered by the need for specific
antisera that are both laborious and time-consuming to
produce, whereas PCR, while being a definite advance in
sensitive virus detection, is prone to failure and false
recordings and is limited in its ability to identify multiple
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Recent advances in DNA and protein microarray methodology and the emerging technology of cell-
based sensors have massively increased the speed and sensitivity with which we can detect viral
infections. The advantages of the multi-parameter microarray technologies could be combined with
the speed and sensitivity of cell-based systems to give ‘cell-omic’ sensors. viruses simultaneously [4]. We therefore need a rapid, sen-
sitive approach that is capable of identifying multiple
viruses in parallel; this need is being addressed by the
development of DNA and protein microarrays specifically
designed for virus detection and identification.
The basic design principle is the same for all forms of
microarray, whether based on DNA, protein or cells. Spe-
cific molecular ‘targets’ are detected simultaneously within
the sample of interest by an array of ‘probes’. The probes,
often numbering thousands, are chemically attached in an
array format to a solid substrate to construct either a DNA
or a protein microarray (Figure 1).  But the microarray
concept is not limited to the use of just DNA or protein
probes. Indeed, in recent years the concept has been greatly
expanded to include the production of all manner of
arrayed probes: cells, glycans and carbohydrates, to name
but a few. The significance of the microarray to the field of
infectious diseases is the parallel detection capabilities of
the system (covered in more detail in [5]). Microarrays offer
the ability to achieve simultaneous detection of many
targets, and through optimization this can be achieved
without detriment to sensitivity.
DNA microarrays for viral analysis can be divided into viral
chips and host chips, and each can be applied not only to
detection and identification but also to the monitoring of
viral populations. In 1999, we and colleagues [6] described
the first viral DNA microarray for the temporal profiling of
viral (human cytomegalovirus, HCMV) gene expression.
Treatment of infected cells with cycloheximide or ganciclovir
was used to block de novo protein synthesis or viral replica-
tion, respectively, and the microarray was then used to gen-
erate expression profiles of the viral genes represented on
the chip. Using this approach, HCMV genes were assigned to
immediate-early, early or late expression classes, depending
on their expression profile in response to the drug treat-
ments. If the expression profile is sufficiently unique, it can
be used as an identifying hybridization signature for the
molecular staging of an infection. 
We described the idea of unique hybridization patterns
being used for the identification of viral inhibitors [6], and in
2002 this idea was applied by Wang et al. [4] to the detec-
tion and identification of viruses. The authors [4] described
the use of viral DNA microarrays to produce hybridization
signatures of viral sequences that effectively serve as ‘viral
barcodes’ for the identification of known, related or novel
viruses. By taking advantage of the highly conserved regions
within gene families, the authors were able to produce an
array that could identify related viruses and discriminate
between serotypes. The ability to distinguish subtypes is criti-
cal to effective infection management in the clinic: variola
virus, for example, is an orthopoxvirus that causes smallpox
and has two subtypes, variola major and variola minor, of dif-
fering pathogenicity. Laassri et al. [7] addressed the problem
of orthopoxvirus subtype discrimination by producing an
array capable of correctly identifying four of the
orthopoxvirus species. Similarly, arrays have been developed
for the detection and distinction of hantaviruses [8] and are
capable of distinguishing between isolates that have up to
90% sequence similarity. Other groups have focused on the
genotyping of viruses such as human immunodeficiency
virus (HIV) and influenza [9,10].
The ability to monitor the divergence of virus strains is critical
for maintaining the effectiveness of current vaccines and
ensuring the safety of vaccines that use live, attenuated
viruses. Cherkasova et al. [11] have demonstrated the use of
oligonucleotide microarrays in the analysis of vaccine-derived
polioviruses. They describe two chip-based approaches. The
‘microarrays for resequencing and sequence heterogeneity’
(MARSH) method uses probes with overlapping sequences
from within the coding region of the gene for the poliovirus
structural polypeptide VP1 to detect point mutations that
have occurred and to determine regions of differing genome
stability. By contrast, the ‘microarray analysis of viral recom-
bination’ (MAVR) method can detect recombination events
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Figure 1
The structure of microarray experiments. (a) To obtain gene-expression
profile data from a cDNA microarray, or chip, RNA is first extracted
from an infected cell. The RNA is then reverse-transcribed and labeled
(‘sample preparation’) and prepared RNA is hybridized to the chip.
(b) Protein microarrays may have either antibodies or antigens arrayed as
probes. Antibody probes can be used to detect antigens from an infected
cell, and vice versa, following sample preparation and labeling. In both
cases (a,b) the hybridized chip is scanned and the image processed to
provide corresponding profiles.
Infected cell
Protein array DNA array
PROTEIN RNA
(a) (b)
Sample preparation
and hybridization
Sample preparation
and hybridization
Image analysis 
Scanning of arraywithin virus strains by analyzing patterns of hybridization to
probes unique to specific virus strains. Used in combination
these chips provide a rapid genotype profile.
Viral chips provide a unique signature derived from the viral
transcriptome or genome alone. An alternative approach is
to examine the host response: changes in host gene expres-
sion provide a molecular signature of infection, an idea
explored by Cummings and Relman [12]. The availability of
commercial chips covering the whole host genome, from
companies such as Affymetrix, allows genome-wide changes
to be examined. Alternatively, smaller customized host chips
can be constructed with a more restricted number of probes.
One of the first groups to adopt this approach identified 258
cellular mRNAs whose level changed by a factor of four or
greater before the onset of HCMV DNA replication [13].
Later, Domachowske et al. [14] examined pneumovirus
strain differences and their ability to induce antiviral inflam-
mation, and van’t Wout et al. [15] examined HIV-1 infection
in CD4+ T cells to identify changes in host gene expression
that were specific to HIV infection and that did not occur in
cells that had been heat shocked, treated with interferon or
infected with influenza A virus. Host gene signatures identi-
fied included pro-inflammatory genes and genes involved in
endoplasmic-reticulum stress pathways, the cell cycle and
apoptosis. A cardinal signature and common molecular
thread for all infections appears to be the markers in the
interferon pathway.
Microarray applications such as those described above offer
an accurate, rapid and sensitive method for the detection
and identification of viruses, but they have important limita-
tions that should be considered. The production of robust
unique hybridization signatures - viral barcodes - which can
be used to correctly identify a viral infection depends on a
number of influencing variables. For example, signatures
may be altered dramatically according to variations in the
viral load, the stage of infection or the tissues sampled.
Obtaining the DNA for hybridization could also be problem-
atic for some infections: infected tissues may be inaccessible
and could yield little nucleic acid.
Protein arrays can also be constructed for the detection and
identification of viruses. Viral antigens can be arrayed and
used to detect serum antibodies, or antibodies can be
arrayed and used to detect pathogens. Bacarese-Hamilton et
al. [16] applied protein microarrays to the detection of anti-
bodies to the protozoan parasite Toxoplasma gondii, rubella
virus, CMV and herpes simplex viruses (HSVs) type 1 and 2.
Antigens were arrayed and used to detect serum immuno-
globins IgG and IgM down to 0.5 pg, and the system was val-
idated by comparison with existing ELISAs. The results
showed 80% agreement between ELISA and array, and con-
firmed that smaller reagent and sample volumes are used by
the array. They also highlighted the advantage of the array’s
internal calibration curve: by processing the calibration
curve on the array and not in separate tubes, as is done in
ELISA, matrix effects that are known to bias ELISAs
were reduced.
Once constructed, protein arrays can be air-dried and easily
stored at room temperature [17]; their production and use
are readily automated and they offer a cost-effective alterna-
tive to ELISAs. In contrast to DNA arrays, protein arrays
cannot provide a readout of global changes in protein
expression, since extensive libraries of globally expressed
proteins simply do not exist [18]. It is still possible, however,
to generate protein analyte ‘signatures’ by using a specific
selection of targeted proteins. For instance, cytokine
responses to viral infection can vary greatly between viruses;
by arraying antibodies to a spectrum of cytokines it is possi-
ble to generate a ‘cytokine signature’ of infection that is
readily identifiable. The application of such technology to
the clinic would, however, require a concerted effort to char-
acterize and collate such cytokine signatures. Considering
that each signature is subject to a number of variables, each
of which can produce a significantly different output, estab-
lishing a catalog of viral identifiers that are consistently
accurate would be no mean feat.
Cell-based detection
Despite the rapidity and sensitivity offered by systems that
use microarray detection and identification, recent work has
demonstrated that it is possible to engineer cell-based
systems that outstrip microarrays in terms of speed of detec-
tion. Rider et al. [19] demonstrated the use of engineered B
cells capable of detecting pathogens within 3 minutes
(Figure 2). Their CANARY sensor (cellular analysis and noti-
fication of antigen risks and yields) comprises B cells that
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Figure 2
The CANARY method (cellular analysis and notification of antigen risks
and yields) [19]. B lymphocytes were engineered to express calcium-
dependent bioluminescent aequorin in the cytosol as well as pathogen-
specific antibodies on the cell surface. Ligation of the antibody by the
pathogen causes an elevation in intracellular calcium ions, thus triggering
emission of light from the aequorin within seconds of pathogen contact. 
Engineered
B lymphocyte
Calcium-sensitive 
bioluminescent aequorin
Pathogen-specific
antibody
Pathogen binding
Elevation of 
intracellular calcium
Light emission
Ca2+express the calcium-dependent bioluminescent protein
aequorin together with membrane-bound pathogen-specific
antibodies. Binding of the pathogen to the cell-surface anti-
bodies triggers an elevation in intracellular calcium ions that
in turn causes the aequorin to emit light, all within a matter
of seconds.  One of the engineered B-cell lines described by
the authors could detect spores of Bacillus anthracis, a
pathogen already feared by the general public in relation to
terror attacks, highlighting the relevance of such a technique.
These investigators [19] used naturally occurring pattern-
recognition molecules - antibodies - but such systems are by
no means restricted to the natural world; for instance,
Golumbfskie et al. [20] have investigated the possibility of
developing synthetic systems capable of specific recognition
between polymers and surfaces. Such biomimetic approaches
may have future applications in both cell-based and
microarray sensor technologies. 
More recently, Perlman et al. [21], have described
multidimensional drug profiling by automated microscopy.
The authors used automated microscopy to create profiles,
analogous to those generated by microarray data, of changes
in cellular phenotype resulting from drug treatment; the
profiles could then be used to categorize various unknown
drugs [21]. This cell-array technique should complement
existing technology and allow rapid, cost-effective collection
of data or individual cellular responses. Although the results
are in the context of drug treatments, one can easily imagine
the application of such a technique to the detection of infec-
tious diseases. A system such as this, capable of creating
profiles based on phenotypic changes in individual cells,
would be a powerful tool.  This technology illustrates how
the ability to measure changes at the molecular level can
allow us to turn individual cells into sensors.
‘Cell-omic’ sensors
Despite the fact that microarray-based technologies are
becoming increasingly rapid, cheap and ever more sensitive,
there are still drawbacks. One approach to maximizing the
effectiveness of existing technology is to combine comple-
mentary technologies (Figure 3). Microarrays provide the
opportunity to develop a system whereby multiple viral
infections can be identified in parallel by their hybridization
signatures or ‘viral barcodes’. Cellular systems, such as the
light-emitting B cells engineered by the Rider group [19],
while individually not having the parallel capabilities of the
array, provide an extremely rapid detection system. In the
future, therefore, we could see the production of hybrid tech-
nologies: ‘cell-omic sensors’, which have the parallel high-
throughput capabilities of arrays coupled with the speed of
the engineered B cells. This may take the form of microarrays
constructed by arraying a panel of engineered cells, for
instance, or even synthetic biomimetic systems. Alterna-
tively, advances could allow arrays to be constructed that
combine cellular sensors with gene or protein probes. It may
be possible to take advantage of the immune system’s
natural pathogen sensors - macrophages or dendritic cells
for example - arrayed onto protein probes or sensors of some
description in such a way that cellular changes induced by
contact with a pathogen can be measured in real time.
The goal of generating hybrid arrays of cells within arrays of
protein probes is increasingly feasible with advances in
science and technology. Ultimately it might be possible to
engineer a ‘microarray’ within a cell, allowing real-time, con-
tinuous monitoring of complex signatures of infection. The
goal of having an addressable array within a cell from which
signals can be measured without perturbing cellular function
may, for example, be enabled through the use of new nano-
materials that act as intermediaries between the biological
system and the physical system used for measurement.
Several types of nanomaterial, such as carbon nanotubes
[22], gold nanoshells [23] and quantum dots [24], have
unique electronic or optical properties that could be tuned to
detect biomolecular concentrations within cells. In these
examples, the nanomaterials may link with systems such as
advanced silicon microelectronics or advanced imaging tech-
niques such as fluorescent lifetime imaging microscopy
(FLIM) or Raman microscopy.
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Figure 3
The concept of ‘cell-omic sensors’. Cell-based detection systems can be
combined with arrayed probes to allow multi-parameter analysis. By
arraying cells in a monolayer on top of probes (such as antibodies), it
would be possible to detect changes in multiple cellular components
simultaneously. Components secreted from the cell or expressed on its
surface could be detected directly by the probes; detection of
intracellular components would require the use of more sophisticated
techniques. Information would be collected directly from the underlying
probes through detection systems positioned below the probes.
Infected sample
Cell-omic sensor
Minimal sample
preparation
Multi-parameter detection
Cells
Probe arrayThere is a strong need for rapid, sensitive pathogen-detec-
tion systems that can be easily applied to the clinic, industry
or even the ‘battlefield’. It is important to acknowledge,
however, that the transition of these technologies from the
bench to real-world application depends on certain require-
ments. A number of groups have produced array data that
could be used to produce viral barcodes or unique identi-
fiers. These efforts, whether at the DNA or protein level, are
currently disparate, uncoordinated and mainly confined to
studies in vitro. A collection of such infection profiles, an
Infection Profile Database, for example, needs to be put
together that sets out standards and requirements that
would help such high-dimensional data to be translated into
clinical utility. Indeed, such information would provide a
valuable resource for constructing specific cell-based sensors
or even synthetic sensors. 
One of the overwhelming problems related to the creation of
unique signatures that will consistently and accurately iden-
tify an infection is the fact that the signatures depend on a
large number of variables. A potential solution might involve
identifying a signature that is produced early in infection
and yet can be sustained for capturing later. This idea is
perhaps not too far-fetched, and it may well involve certain
immune cells, in particular those destined to become
antigen-driven memory cells. Although various responses
can be used to identify an infection, the heterogeneity of the
system we propose (Figure 3) may be too variable, and thus
the detection of these responses would require all patients to
present within a very narrow characterized window for their
output to be informative. In clinical terms, this scenario is
obviously completely unrealistic. The question is whether
infections leave early footprints that are unique and read-
able, or whether the response to infection as a whole is
simply too dynamic. Answers to these questions are
tractable but will require carefully controlled and appropri-
ately powered studies as well as standardization of data mea-
surements and quality assurance. Increasing attention is
being given to these critical areas, and as a consequence we
are in exciting times in this rapidly moving field.
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